Thrombin activatable fibrinolysis inhibitor inhibits fibrinolysis by removing C-terminal lysine residues from partially degraded fibrin. It is expressed by the liver and circulates in plasma as a zymogen TAFI, which can be activated to an active carboxypeptidase, TAFIa, by plasmin or thrombin. Thrombomodulin in complex with thrombin increased the activation 1250-fold. The active carboxypeptidase TAFIa is unstable with a half-life of about 10 min at 37 °C and is inactivated to TAFIai by conformational change.

Thesis (M.Med.(Haematology))--University of the Witwatersrand, Faculty of Health Sciences, 2003.

Thesis (M.A.)--Boston University / PLEASE NOTE: Boston University Libraries did not receive an Authorization To Manage form for this thesis or dissertation. It is therefore not openly accessible, though it may be available by request. If you are the author or principal advisor of this work and would like to request open access for it, please contact us at open-help@bu.edu. Thank you. / 2031-01-01

No description available.

Thesis (MAppSc)--University of South Australia, 1997

Thesis (MAppSc)--University of South Australia, 1998

Diss. (sammanfattning) Stockholm : Karol. inst. / Härtill 6 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst. / Härtill 6 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst. / Härtill 5 uppsatser.

Thesis (M.D.) -- Dept. of Medicine, University of Adelaide, 1974.